Dr. Csaky is a tenured associate professor in the Department of Ophthalmology at Duke University in Durham, North Carolina. Previously he was a tenured senior investigator at the National Eye Institute, (NEI), where he ran the Laboratory of Retinal Diseases and Therapeutics. He received his combined medical and doctorate degrees from the University of Louisville, Kentucky. Following residency in Internal Medicine at Duke University, he was awarded a Fulbright Scholarship and worked with Professor Meyer-Schwickerath in Essen, Germany. He completed his Ophthalmology residency at Washington University in St. Louis and a Retina fellowship at the Wilmer Eye Institute. These were followed by a 3-year post-doctoral fellowship at the National Cancer Institute.
Dr. Csaky’s main area of research is age-related macular degeneration (AMD), for which he conducts both laboratory and clinical research. He was the study chair for the Phase II Celebrex with Photodynamic Therapy (Visudyne) Trial (C-PDT) and the Phase II Verteporfin and Triamcinolone Acetonide (VERTACL-1) and Bevacizumab (VERTACL-2) Trials. In addition, he has conducted numerous phase I trials in AMD. His lab is studying the pathogenesis of all forms of AMD, investigating the use of sustained drug delivery as a therapeutic modality. Dr. Csaky is a member of the American Academy of Ophthalmology, the Macula Society, and the Association for Research in Vision and Ophthalmology (ARVO).